Circadian genes polymorphisms, night work and prostate cancer risk: Findings from the EPICAP study.
ARNTL Transcription Factors
/ genetics
Adult
Aged
Basic Helix-Loop-Helix Transcription Factors
/ genetics
Case-Control Studies
Circadian Clocks
Genetic Predisposition to Disease
Genotyping Techniques
Humans
Logistic Models
Male
Middle Aged
Neoplasm Grading
Nerve Tissue Proteins
/ genetics
Nuclear Receptor Subfamily 1, Group F, Member 1
/ genetics
Polymorphism, Single Nucleotide
Prostatic Neoplasms
/ genetics
Shift Work Schedule
/ adverse effects
circadian genes
interaction
night work
pathway analysis
polymorphisms
prostate cancer
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
received:
30
09
2019
revised:
04
05
2020
accepted:
18
05
2020
pubmed:
9
6
2020
medline:
17
4
2021
entrez:
8
6
2020
Statut:
ppublish
Résumé
Over the past two decades, several studies have attempted to understand the hypothesis that disrupting the circadian rhythm may promote the development of cancer. Some have suggested that night work and some circadian genes polymorphisms are associated with cancer, including prostate cancer. Our study aims to test the hypothesis that prostate cancer risk among night workers may be modulated by genetic polymorphisms in the circadian pathway genes based on data from the EPICAP study, a population-based case-control study including 1511 men (732 cases/779 controls) with genotyped data. We estimated odds ratio (ORs) and P values of the association between prostate cancer and circadian gene variants using logistic regression models. We tested the interaction between circadian genes variants and night work indicators that were significantly associated with prostate cancer at pathway, gene and SNP levels. Analyses were also stratified by each of these night work indicators and by cancer aggressiveness. The circadian pathway was significantly associated with aggressive prostate cancer among night workers (P = .004), particularly for men who worked at night for <20 years (P = .0002) and those who performed long night shift (>10 hours, P = .001). At the gene level, we observed among night workers significant associations between aggressive prostate cancer and ARNTL, NPAS2 and RORA. At the SNP-level, no significant association was observed. Our findings provide some clues of a potential modulating effect of circadian genes in the relationship between night work and prostate cancer. Further investigation is warranted to confirm these findings and to better elucidate the biological pathways involved.
Substances chimiques
ARNTL Transcription Factors
0
BMAL1 protein, human
0
Basic Helix-Loop-Helix Transcription Factors
0
NPAS2 protein, human
0
Nerve Tissue Proteins
0
Nuclear Receptor Subfamily 1, Group F, Member 1
0
RORA protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3119-3129Informations de copyright
© 2020 UICC.
Références
Grosclaude P, Belot A, Daubisse Marliac L, et al. Prostate cancer incidence and mortality trends in France from 1980 to 2011. Prog Urol. 2015;25:536-542.
IMV Group. Carcinogenicity of night shift work. Lancet Oncol. 2019;20:1058-1059.
Straif K, Baan R, Grosse Y, et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007;8:1065-1066.
Wendeu-Foyet MG, Menegaux F. Circadian disruption and prostate cancer risk: an updated review of epidemiological evidences. Cancer Epidemiol Biomarkers Prev. 2017;26:985-991.
Wendeu-Foyet MG, Bayon V, Cénée S, et al. Night work and prostate cancer risk: results from the EPICAP study. Occup Environ Med. 2018;75:573-581.
Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002;111:41-50.
Saha S, Sassone-Corsi P. Circadian clock and breast cancer: a molecular link. Cell Cycle. 2007;6:1329-1331.
Gery S, Virk R, Chumakov K, Yu A, Koeffler H. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene. 2007;26:7916-7920.
Hoffman AE, Zheng T, Ba Y, Zhu Y. The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res. 2008;6:1461-1468.
Lee CC. Tumor suppression by the mammalian period genes. Cancer Causes Control. 2006;17:525-530.
Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang C, Wang X, Wang Z, Cornelissen-Guillaume G, Halberg F. Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci 2006;97: 589-96.
Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006;22:375-382.
Xiang S, Coffelt SB, Mao L, Yuan L, Cheng Q, Hill SM. Period-2: a tumor suppressor gene in breast cancer. J Circadian Rhythms. 2008;6:4.
Valenzuela F, Vera J, Venegas C, et al. Evidences of polymorphism associated with circadian system and risk of pathologies: a review of the literature. Int J Endocrinol. 2016;2016:1-12.
Cuninkova L, Brown SA. Peripheral circadian oscillators: interesting mechanisms and powerful tools. Ann N Y Acad Sci. 2008;1129:358-370.
Karantanos T, Theodoropoulos G, Pektasides D, Gazouli M. Clock genes: their role in colorectal cancer. World J Gastroenterol: WJG. 2014;20:1986-1992.
Wendeu-Foyet MG, Koudou Y, Cenee S, et al. Circadian genes and risk of prostate cancer: findings from the EPICAP study. Int J Cancer. 2019;145:1745-1753.
Chu L, Zhu Y, Yu K, et al. Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis. 2008;11:342-348.
Chu LW, Till C, Yang B, et al. Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog. 2018;57:462-466.
Gu F, Zhang H, Hyland PL, et al. Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia. Int J Cancer. 2017;141:1794-1802.
Markt SC, Valdimarsdottir UA, Shui IM, et al. Circadian clock genes and risk of fatal prostate cancer. Cancer Causes Control. 2015;26:25-33.
Zhu Y, Stevens RG, Hoffman AE, et al. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res. 2009;69:9315-9322.
Benna C, Helfrich-Forster C, Rajendran S, et al. Genetic variation of clock genes and cancer risk: a field synopsis and meta-analysis. Oncotarget. 2017;8:23978-23995.
Mocellin S, Tropea S, Benna C, Rossi CR. Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies. BMC Med. 2018;16:20.
Menegaux F, Anger A, Randrianasolo H, et al. Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France. BMC Cancer. 2014;14:106.
Amos CI, Dennis J, Wang Z, et al. The OncoArray consortium: a network for understanding the genetic architecture of common cancers. Cancer Epidemiol Biomarkers Prev. 2017;26:126-135.
Yu K, Li Q, Bergen AW, et al. Pathway analysis by adaptive combination of P-values. Genet Epidemiol. 2009;33:700-709.
Broc C, Evangelou M, Guenel P, Truong T, Liquet B. Investigating gene-and pathway-environment interaction analysis approaches. J Soc Française Stat. 2018;159:56-83.
Takahashi JS. Transcriptional architecture of the mammalian circadian clock. Nat Rev Genet. 2017;18:164-179.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B Methodol. 1995;57:289-300.
Rabstein S, Harth V, Justenhoven C, et al. Polymorphisms in circadian genes, night work and breast cancer: results from the GENICA study. Chronobiol Int. 2014;31:1115-1122.
Zienolddiny S, Haugen A, Lie JA, Kjuus H, Anmarkrud KH, Kjaerheim K. Analysis of polymorphisms in the circadian-related genes and breast cancer risk in Norwegian nurses working night shifts. Breast Cancer Res. 2013;15:R53.
Grundy A, Schuetz JM, Lai AS, et al. Shift work, circadian gene variants and risk of breast cancer. Cancer Epidemiol. 2013;37:606-612.
Truong T, Liquet B, Menegaux F, et al. Breast cancer risk, nightwork, and circadian clock gene polymorphisms. Endocr Relat Cancer. 2014;21:629-638.
Monsees GM, Kraft P, Hankinson SE, Hunter DJ, Schernhammer ES. Circadian genes and breast cancer susceptibility in rotating shift workers. Int J Cancer. 2012;131:2547-2552.
Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 2003;3:350-361.
Mullenders J, Fabius AW, Madiredjo M, Bernards R, Beijersbergen RL. A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One. 2009;4:e4798.
Merbitz-Zahradnik T, Wolf E. How is the inner circadian clock controlled by interactive clock proteins?: structural analysis of clock proteins elucidates their physiological role. FEBS Lett. 2015;589:1516-1529.
Lee S, Donehower LA, Herron AJ, Moore DD, Fu L. Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS One. 2010;5:e10995.
Dai H, Zhang L, Cao M, et al. The role of polymorphisms in circadian pathway genes in breast tumorigenesis. Breast Cancer Res Treat. 2011;127:531-540.
Lin DW, FitzGerald LM, Fu R, et al. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev. 2011;20:1928-1936.
Jia L, Sun Y. SCF E3 ubiquitin ligases as anticancer targets. Curr Cancer Drug Targets. 2011;11:347-356.
Jia L, Soengas MS, Sun Y. ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res. 2009;69:4974-4982.
Rana S, Mahmood S. Circadian rhythm and its role in malignancy. J Circadian Rhythms. 2010;8:3.
Du J, Xu R. RORalpha, a potential tumor suppressor and therapeutic target of breast cancer. Int J Mol Sci. 2012;13:15755-15766.
Huang FY, Chiu PM, Tam KF, et al. Semi-quantitative fluorescent PCR analysis identifies PRKAA1 on chromosome 5 as a potential candidate cancer gene of cervical cancer. Gynecol Oncol. 2006;103:219-225.
Faubert B, Boily G, Izreig S, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013;17:113-124.
Evangelou M, Rendon A, Ouwehand WH, Wernisch L, Dudbridge F. Comparison of methods for competitive tests of pathway analysis. PLoS One. 2012;7:e41018.